Open AccessVemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Author(s) -
Lara Dunn,
Eric J. Sherman,
Shrujal S. Baxi,
Vatche Tchekmedyian,
Ravinder K. Grewal,
Steven M. Larson,
Keith S. Pentlow,
Sofia Haque,
R. Michael Tuttle,
Mona M. Sabra,
Stephanie Fish,
Laura Boucai,
Jamie Walters,
Ronald Ghossein,
Venkatraman Seshan,
Ai Ni,
Li Duan,
Jeffrey A. Knauf,
David G. Pfister,
James A. Fagin,
Alan L. Ho
Publication year - 2018
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2018-01478
Subject(s) - vemurafenib , medicine , thyroglobulin , thyroid cancer , cancer research , thyroid , mapk/erk pathway , oncology , refractory (planetary science) , cancer , endocrinology , kinase , biology , metastatic melanoma , microbiology and biotechnology , astrobiology
BRAFV600E mutant thyroid cancers are often refractory to radioiodine (RAI).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom